A Phase I/II Dose Escalation Trial of HDAC Inhibitor Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 22 Sep 2017
At a glance
- Drugs Tefinostat (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 18 Sep 2017 Planned End Date changed from 1 Sep 2017 to 1 Jun 2018.
- 18 Sep 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Jun 2018.
- 18 Sep 2017 Status changed from recruiting to active, no longer recruiting.